Detail View

Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation
Citations

WEB OF SCIENCE

Citations

SCOPUS

Metadata Downloads

Title
Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation
Issued Date
2016-04-26
Citation
Hong, SungWoo. (2016-04-26). Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation. Oncotarget, 7(17), 23482–23497. doi: 10.18632/oncotarget.8112
Type
Article
Author Keywords
cancer stem cellshepatocellular carcinomaradioresistanceADAM17migration
Keywords
ADAM17BREAST-CANCERCancer Stem CellsDEFINITIVE RADIOTHERAPYENDOTHELIAL GROWTH-FACTOREPITHELIAL-MESENCHYMAL TRANSITIONEXPRESSIONHepatocellular CarcinomaHUMAN HEPATOCELLULAR-CARCINOMAMetastasisMIGRATIONNOTCH PATHWAYRadioresistanceTUMOR-GROWTH
ISSN
1949-2553
Abstract
We investigated the biological role of CD133-expressing liver cancer stem cells (CSCs) enriched after irradiation of Huh7 cells in cell invasion and migration. We also explored whether a disintegrin and metalloproteinase-17 (ADAM17) influences the metastatic potential of CSC-enriched hepatocellular carcinoma (HCC) cells after irradiation. A CD133-expressing Huh7 cell subpopulation showed greater resistance to sublethal irradiation and specifically enhanced cell invasion and migration capabilities. We also demonstrated that the radiation-induced MMP-2 and MMP-9 enzyme activities as well as the secretion of vascular endothelial growth factor were increased more predominantly in Huh7CD133+ cell subpopulations than Huh7CD133- cell subpopulations. Furthermore, we showed that silencing ADAM17 significantly inhibited the migration and invasiveness of enriched Huh7CD133+ cells after irradiation; moreover, Notch signaling was significantly reduced in irradiated CD133-expressing liver CSCs following stable knockdown of the ADAM17 gene. In conclusion, our findings indicate that CD133-expressing liver CSCs have considerable metastatic capabilities after irradiation of HCC cells, and their metastatic capabilities might be maintained by ADAM17. Therefore, suppression of ADAM17 shows promise for improving the efficiency of current radiotherapies and reducing the metastatic potential of liver CSCs during HCC treatment.
URI
http://hdl.handle.net/20.500.11750/2693
DOI
10.18632/oncotarget.8112
Publisher
Impact Journals LLC
Show Full Item Record

File Downloads

  • There are no files associated with this item.

공유

qrcode
공유하기

Total Views & Downloads